Drug intelligence / Profile preview

Prostate cancer vaccine ONY-P1

Development stage: Phase 2
Lead developer: Onyvax
Modality: Vaccines & Immunotherapeutics
Administration: Intradermal

Overview

Prostate cancer vaccine ONY-P1 is an investigational therapeutic cancer vaccine derived from three irradiated allogeneic prostate cancer cell lines. These cell lines represent different stages of prostate cancer and express a broad range of prostate and prostate cancer antigens, aiming to stimulate the immune system to recognize and attack prostate tumor cells. The primary indication for this therapy is prostatic (prostate) cancer, with development led by Onyvax Ltd. Clinical studies have reached Phase 2 for metastatic and advanced forms of the disease[1][2].

Other names: prostate cancer vaccine ONY-P1

Beyond the preview

Go deeper on Prostate cancer vaccine ONY-P1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Prostate cancer vaccine ONY-P1.

Explore the full profile